Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.82 - $4.24 $29,203 - $43,909
10,356 Added 262.04%
14,308 $45,000
Q2 2022

Aug 15, 2022

BUY
$2.14 - $5.23 $8,457 - $20,668
3,952 New
3,952 $11,000

Others Institutions Holding GRPH

About Graphite Bio, Inc.


  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track This Portfolio

Track Cannell Capital LLC Portfolio

Follow Cannell Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannell Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cannell Capital LLC with notifications on news.